Nasdaq : $JUPW announced it has concluded an Asset
Post# of 102250
"This strategic asset purchase agreement adds immediate revenues to Jupiter in Q2 2022 and contributes positively towards EBITDA with no upfront cash or stock acquisition cost to our company. The acquired contracts and related assets enhance Jupiter's position as a research and development powerhouse while allowing us to enter the lucrative clinical research organization business," stated Jupiter CEO Brian John. https://finance.yahoo.com/news/jupiter-wellne...00618.html